TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70
TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.
Stocks · News reference
U.S. stock futures mixed, Nasdaq 100 up 100 points. FedEx falls after Q4 results, beating estimates but reporting reduced operating margin. Other stocks also down in pre-market.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $75 to $70.
HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.
Cerebras stock has declined 52% from its May peak despite strong fundamentals, with core revenue doubling year-over-year and management raising full-year guidance. However, at ~145x forward earnings, the valuation remains extremely high. The company has a $25.4 billion backlog (largely from an OpenAI agreement) but still operates at a loss. For the current price to justify itself, earnings must grow significantly, requiring years of execution with little room for timing delays.
The article compares two AI-focused tech stocks: BigBear.ai, which provides decision intelligence solutions for government and defense logistics, and Cerebras Systems, which manufactures wafer-scale processors for AI training. Cerebras is recommended as the better investment due to consistent high growth (74% YoY in Q2 2026) and strong profitability (47% net margin), while BigBear.ai faces revenue inconsistency, customer concentration risks, and ongoing legal challenges despite showing some growth catalysts from increased defense spending.
Ark Invest sold Palantir and AMD shares on Tuesday, Sept. 8, 2026, while buying into Robinhood and Cerebras through ARKK.